Mednarodni projekti
Enabling Techniques for the Development of a Novel Class of Protein Antibiotics
Organizacije (1)
Povzetek
Antibiotics resistance of pathogens is a major threat to public health and safety. The rapid spread of resistant strains increases the risk of epidemics. This issue also includes preparedness to deal with bio-terrorism. The objectives of the ET-PA project are to develop an open, generic platform to enable the development of new classes of protein-antibiotics. The key technology (REPPs) is based on a principle that is proprietary to one of the participating SMEs, consisting of rationally modified class II restriction enzymes (RE) fused to cell penetration peptide sequences (PP) that selectively allow microbial cell penetration. Introduction of a REPP system into pathogens would lead to effective cell killing. The REPP will be designed to inactivate major microbial pathogens, i.e. S. aureus, P. aeruginosa and C. Albicans. Addressing these ambitious objectives will require a Co-operative Research setup with complementing expertise and resources, coming both from high-tech SMEs and expert academic RTD partners. The ET-PA project will be divided into four work packages:1.Discovery -The design of a technology platform for the discovery of PP sequences for proper function in antibiotic REPP constructs.2.Characterization -extensive characterization of the biological activity of antibiotic REPP constructs.3.Technological platform - configuration of a semi-automatic and embedding technology platform that enables a coherent and unified approach for a rapid translation of REPP components into protein antibiotics.4.Management - to assure, consolidation and coordination of the ET-PA project, support and protection of Intellectual Property, and contacts to subsequently license the outcomes to a third-party end-user.The commitment and collective efforts of all participants is the best warranty for a success of the ET-PA project that will provide a technology platform to translate the most effective horizontal bacterial defence system into innovative medicine.
